Afimkibart not checked

Roche · PF-06480605 · Cohorts 1 and 2 Active

FollowEvery change as it happens, and a Monday email
Stage
 
Next date
Phase 2 trial completes
Trials
14 active
19 in total · 10 in the EU
Targets
 

What this is

How it works
An antibody: a lab-made immune protein built to latch onto one target in the body.-bart: artificial immunoglobulins WHO name stem
How it’s given
“Participants will receive afimkibart IV followed by afimkibart subcutaneous SC injection.”In the company’s words, NCT06588855 on ClinicalTrials.gov
Tested for
Moderately to Severely Active Ulcerative Colitis (4 trials), Moderately to Severely Active Crohns Disease (3 trials), Atopic Dermatitis (2 trials), Rheumatoid Arthritis (2 trials), Crohns Disease, MASH, Active Ulcerative Colitis
Main trialPhase 3
“This Phase III, multicenter, double-blind, placebo-controlled study will evaluate the efficacy and safety of induction therapy with Afimkibart (RO7790121) compared with placebo in participants with moderately to severely active ulcerative colitis (UC).”In the company’s words, NCT06588855 on ClinicalTrials.gov
Other names
PF-06480605 · Cohorts 1 and 2 Active · RO7790121 · RVT-3101 · RG6631

Other drugs for Moderately to Severely Active Ulcerative Colitis

All 79 drugs for Moderately to Severely Active Ulcerative Colitis

Coming up11

Changes0

Last 90 days

No changes yet. We started recording changes on 6 Nov 2026.

Trials19

TrialPhaseCompletesWhat it tests
Phase 3Active, not recruiting 29 Oct 2026 A Study to Assess the Efficacy and Safety of Induction Therapy With Afimkibart (Also Known as RO7790121) in Participants With Moderately to Severely Active Ulcerative Colitis
Phase 3Active, not recruiting 30 Jan 2027 A Study to Assess the Efficacy and Safety of Afimkibart (Also Known as RO7790121) for Induction and Maintenance Therapy in Participants With Moderately to Severely Active Ulcerative Colitis
Phase 3Recruiting 31 May 2028 A Study to Assess the Efficacy and Safety of Subcutaneous Induction Therapy With Afimkibart in Participants With Moderately to Severely Active Ulcerative Colitis
Phase 3Recruiting 31 Dec 2028 A Study to Assess the Efficacy and Safety of Induction and Maintenance Therapy With Afimkibart (RO7790121) in Participants With Moderately to Severely Active Crohn's Disease
Phase 3Recruiting 31 Dec 2028 A Study to Assess the Efficacy and Safety of Induction Therapy With Afimkibart (RO7790121) in Participants With Moderately to Severely Active Crohn's Disease
Phase 3Recruiting 31 Mar 2030 A Study to Evaluate the Pharmacokinetics, Safety and Efficacy of Afimkibart (RO7790121) in Children With Moderately to Severely Active Ulcerative Colitis
Phase 3Recruiting 31 May 2030 A Study to Assess the Pharmacokinetics, Effectiveness and Safety of Afimkibart for Induction and Maintenance Therapy in Children With Moderately to Severely Active Crohn's Disease
Phase 2Active, not recruiting 22 Jul 2026 A Study to Assess the Efficacy and Safety of Afimkibart (RO7790121) in Participants With Moderate to Severe Atopic Dermatitis
Phase 2Active, not recruiting 31 Dec 2026 Afimkibart (RO7790121) for the Treatment of Moderate to Severe Active Crohn's Disease
Phase 2Recruiting 17 Apr 2027 A Study to Assess the Efficacy and Safety of RO7790121 in Participants With Moderate to Severe Rheumatoid Arthritis Who Have Not Responded to or Who Cannot Tolerate Tumor Necrosis Factor (TNF) and/or Janus Kinase (JAK Inhibitors)
Phase 2Active, not recruiting 1 Mar 2033 A Long Term Extension Study to Evaluate the Safety and Efficacy of Afimkibart (RO7790121) in Participants With Atopic Dermatitis
Phase 2Recruiting 8 Jul 2033 An Extension Study to Assess Long-Term Safety and Efficacy of Afimkibart in Participants With Rheumatoid Arthritis
Phase 1Active, not recruiting 24 Sep 2026 A Study to Assess the Safety, Pharmacokinetics, and Activity of RO7790121 in Participants With Advanced MASH Liver Fibrosis
Phase 1Recruiting 31 Jul 2027 An Early-Stage Study in Multiple Clinics of How Afimkibart May Affect the Body's Processing of Medicines That Rely on Cytochrome P450 Enzymes in Participants With Ulcerative Colitis
Phase 2Completed 31 May 2018 Safety, Efficacy, and Tolerability Study of PF-06480605 in Subjects With Moderate to Severe Ulcerative Colitis.
Phase 2Completed 25 Oct 2022 A Study to Evaluate the Efficacy and Safety of PF-06480605 in Adults With Moderate to Severe Ulcerative Colitis
Phase 2Withdrawn 15 Aug 2026 Study to Evaluate the Efficacy and Safety of PF-06480605 in Adult Participants With Moderate to Severe Crohn's Disease
Phase 1Completed Mar 2015 Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single Intravenous and Multiple Subcutaneous and Intravenous Doses of PF-06480605 in Healthy Subjects.
Phase 1Completed 11 Nov 2020 Evaluation of Safety, Tolerability and Pharmacokinetics of Single Dose of PF-06480605 in Japanese Healthy Participants
A trial in both registries shows both numbers.

About

Sources
ClinicalTrials.gov updated 18 Nov 2026 · EU trials register (CTIS) updated 18 Nov 2026 · openFDA updated 17 Nov 2026

Follow Afimkibart

Following is part of Solo: you see every change to Afimkibart the day it happens.

Solo

$49a month, excl. VAT

  • Follow up to 5 landscapes, companies or drugs
  • Every change, the day it happens
  • A Monday email with the week’s changes
Choose Solo

Free

$0no card

  • One landscape of your own, in full
  • The top 10 of everything else
Sign up free

Have an account? Sign in